The DUSP3 Knockout Huh-7 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Huh-7 human hepatocellular carcinoma cell line, providing a robust loss-of-function model for studying the dual-specificity phosphatase DUSP3. This polyclonal knockout cell population is produced by CRISPR/Cas9-mediated gene disruption of the DUSP3 locus, eliminating expression of the endogenous phosphatase without selection of a single clone. The product is supplied as a heterogeneous pool of edited cells, suitable for experiments requiring population-level assessment of DUSP3 ablation in a liver cancer context.
The Huh-7 host cell line is a well-differentiated human hepatocellular carcinoma line originally established from a liver tumor of a 57-year-old Japanese male. Huh-7 cells are widely used as a model system for hepatocellular carcinoma research, particularly in studies of tumor biology, oncogenic signaling, and drug metabolism. Their epithelial morphology, stable growth characteristics, and retention of many hepatocyte-specific functions make them a valuable substrate for gene-editing approaches aimed at dissecting molecular mechanisms in liver cancer.
DUSP3 encodes a dual-specificity phosphatase that negatively regulates mitogen-activated protein kinase (MAPK) signaling by dephosphorylating both phosphotyrosine and phosphothreonine residues on ERK1/2 and JNK1/2. This activity attenuates downstream transcriptional responses and serves as a critical brake on cell proliferation, differentiation, and survival. DUSP3 is a recognized tumor suppressor in liver cancer, and its upstream regulators include p53, DNA damage, oxidative stress, and EGFR signaling. Interacting factors and downstream targets comprise ERK1/2, JNK1/2, EGFR, and STAT5, with representative pathway components such as GRB2, RAS, RAF, and MEK1/2 integrating signals from receptors to MAP kinases.
In the Huh-7 hepatocellular carcinoma background, loss of DUSP3 is predicted to sustain MAPK pathway activation, thereby promoting uncontrolled proliferation and apoptotic resistance. This knockout model enables researchers to examine the functional consequences of DUSP3 ablation on tumorigenic properties, including cell cycle progression, survival signaling, and response to therapeutic agents. The polyclonal nature of the knockout population avoids potential clonal artifacts while providing a physiologically relevant system to assess the tumor-suppressive role of DUSP3 in a liver cancer milieu.
Typical research applications include investigation of DUSP3-dependent regulation of hepatocellular carcinoma proliferation, apoptosis, and drug resistance. Researchers can monitor MAPK pathway activity via Western blotting for phosphorylated ERK1/2 and JNK, perform cell proliferation and colony formation assays, and quantify apoptosis induction. RT-qPCR analysis of downstream target genes such as CCND1 and MYC further delineates transcriptional effects, and xenograft tumor growth models permit in vivo evaluation of tumor suppression. For further information, please contact Ascent Research.
